EUVIMEDEUVIMED entdecken
Open Access

Carotid Endarterectomy Should Not Be Recommended to End-Stage Kidney Disease Patients with Asymptomatic Carotid Artery Disease

Muhammad Saad Hafeez, Othman M Abdul-Malak, Mohammad H Eslami, Rabih A Chaer, Theodore H Yuo

Annals of Vascular Surgery · 2024

DOI: 10.1016/j.avsg.2023.08.031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Vascular Surgery, 2024. Verfasst von Muhammad Saad Hafeez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address: saad.hafeez@alumni.aku.edu. Hauptthemen laut MEDLINE: Endarterectomy, Carotid, Carotid Stenosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Carotid Artery Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, University of Pittsburgh.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Carotid endarterectomy (CEA) for asymptomatic carotid artery disease is advised for patients with low perioperative stroke risk and life expectancy of 3-5 years. We sought to explore the role of risk stratification and postoperative medical management in identifying appropriate asymptomatic candidates for CEA in the end-stage kidney disease (ESKD) population. METHODS: We identified ESKD patients on dialysis from the United States Renal Data System that underwent CEA (2008-2014) for asymptomatic carotid artery disease. We used the Liu comorbidity index as well as a novel risk prediction model based on Cox proportional hazards model to stratify patients. The primary outcome evaluated was 3-year survival, and Kaplan-Meier methods were used to generate survival estimates. We further conducted a subanalysis of patients with Medicare part D data to determine postoperative usage of the following medications: statins, antiplatelets, and antihypertensives. We evaluated the association of medication utilization and 3-year survival using Kaplan-Meier methods and Cox proportional hazards modeling. RESULTS: We analyzed 1,813 patients meeting inclusion criteria. The population was predominantly older (mean age 70.2 ± 9.1), White (84.8%), and had a high prevalence of cardiovascular comorbidities, such as hypertension (90.7%), diabetes (62.5%), and congestive heart failure (35.4%). Among the entire cohort, 23.0% had a Liu comorbidity index ≤8, 35.0% had index 9-12, and 42.0% had index >12. Increasing Liu comorbidity index was associated with worse survival (P 80 (adjusted hazard ratio [aHR] = 2.49, 95% confidence interval [CI] [1.87-3.33], P 12(aHR = 1.89, 95% CI [1.56-2.28], P 4 (15.4%). Increasing risk score was associated with worse survival (P < 0.01) but even the "low-risk" group had 3-year survival of 58.5% (54.9-61.9). Subanalysis of the 1,249 (68.8% of total) patients with part D data found that statins and calcium channel blocker use was associated with improved survival, although observed rates for patients on drug were still low. CONCLUSIONS: The overall long-term survival of ESKD patients undergoing CEA for asymptomatic carotid artery disease is low. Risk stratification and analysis of postoperative medical management did not identify a subgroup of patients with adequate 3-year survival. Hence, the preventive benefits of CEA are not realized in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endarterectomy, CarotidCarotid StenosisHydroxymethylglutaryl-CoA Reductase InhibitorsCarotid Artery DiseasesKidney Failure, ChronicStrokeHeart FailureHumansAgedUnited StatesMiddle AgedRisk AssessmentTreatment OutcomeMedicareRisk FactorsRetrospective Studies

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address: saad.hafeez@alumni.aku.edu.
  • Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
  • Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. Electronic address: yuoth@upmc.edu.

Förderung

  • NHLBI NIH HHS
  • University of Pittsburgh

Zitieren

APA

Hafeez, M. S., Abdul-Malak, O. M., Eslami, M. H., Chaer, R. A., & Yuo, T. H. (2024). Carotid Endarterectomy Should Not Be Recommended to End-Stage Kidney Disease Patients with Asymptomatic Carotid Artery Disease. Annals of Vascular Surgery. https://doi.org/10.1016/j.avsg.2023.08.031

Vancouver

Hafeez MS, Abdul-Malak OM, Eslami MH, Chaer RA, Yuo TH. Carotid Endarterectomy Should Not Be Recommended to End-Stage Kidney Disease Patients with Asymptomatic Carotid Artery Disease. Annals of Vascular Surgery. 2024. doi:10.1016/j.avsg.2023.08.031

BibTeX
@article{Hafeez2024,
  author = {Hafeez, Muhammad Saad and Abdul-Malak, Othman M and Eslami, Mohammad H and Chaer, Rabih A and Yuo, Theodore H},
  title = {Carotid Endarterectomy Should Not Be Recommended to End-Stage Kidney Disease Patients with Asymptomatic Carotid Artery Disease},
  journal = {Annals of Vascular Surgery},
  year = {2024},
  doi = {10.1016/j.avsg.2023.08.031}
}
Kostenlos starten →